Therefore, we propose that in addition to the described function of silencing B cell differentiation genes59, EZH2 gain-of-function mutations may also activate an MLL–MEN1-dependent oncogenic gene expression program to facilitate DLBCL pathogenesis (Fig. 5h). The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.